Title
Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Amsterdam ,
Subject
Human medicine
Source (journal)
European journal of cancer : supplements. - Amsterdam, 1990, currens
Volume/pages
10(2012) :1 , p. 105-111
ISSN
1359-6349
1878-1217
ISI
000302130800017
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Affiliation
University of Antwerp
Abstract
Since1964, the EORTC Lymphoma Group has conducted nine consecutive randomized phase III trials on early-stage Hodgkin lymphoma aimed at increasing efficacy while decreasing short- and long-term toxicities. Event-free and overall survival significantly improved from about 50% and 70%, respectively, in the early years to over 80% and 90%, respectively, more recently. Identification of prognostic subgroups appeared to be a successful method to tailor treatment strategies. Radiotherapy fields have become more restricted whereas chemotherapy has become standard. Early PET-CT has been introduced to investigate the possibility of treatment adaptation. Longitudinal quality-of-life assessment has become an integral part of our studies. An ongoing study focuses on the rehabilitation and quality of long-term survival in all 6658 Hodgkin lymphoma patients treated in EORTC trials since the earliest beginning. In advanced stages overall outcome has improved as well with 10-year survival rates of over 75%. (C) 2012 European Organisation for Research and Treatment of Cancer. All rights reserved.
Full text (open access)
https://repository.uantwerpen.be/docman/irua/3b93c2/5234.pdf
Handle